Loading
A phase 2 trial of Docetaxel, Bevacizumab, Pemetrexed and Carboplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] is a phase 2 interventional study registered as NCT06783647 by Nanjing Leads Biolabs Co.,Ltd, with 250 participants planned, started 2025-06-11 and due to reach its primary completion in 2026-12-24. Interventions recorded: LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection, Pemetrexed Disodium for Injection, Paclitaxel Injection and Carboplatin Injection.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Docetaxel, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Docetaxel, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.